CG Oncology (CGON) Earnings Call Presentation

Cretostimogene Clinical Programs & Efficacy - Cretostimogene targets over 70% of the Non-Muscle Invasive Bladder Cancer (NMIBC) market[10] - In High-Risk BCG-Unresponsive NMIBC CIS, Cretostimogene monotherapy (BOND-003 Cohort C) achieved a 12-month Complete Response (CR) rate of 46.4% (51 out of 110 patients) and an estimated 24-month CR rate of 42.3%[30] - In High-Risk BCG-Unresponsive NMIBC Ta/T1 (BOND-003 Cohort P), Cretostimogene demonstrates a 90.5% High Grade Recurrence-Free Survival (HG-RFS) rate at 3, 6, and 9 months[16, 54] - In CORE-008 CX (Cretostimogene in combination with gemcitabine), the Overall Complete Response was 75%[61] Safety & Durability - Cretostimogene demonstrates best-in-disease durability data, with a median Duration of Response (DoR) exceeding 28 months and ongoing in HR BCG-UR NMIBC[12, 38] - 97.3% of patients treated with Cretostimogene were free from progression to MIBC at 24 months[14, 32] - 91.6% of responders avoided radical cystectomy by month 24[14, 32] - Cretostimogene has a favorable safety profile, with 0% Grade ≥ 3 treatment-related Adverse Events (AEs) reported[12, 43, 45] Trial Updates & Market Position - The Phase 3 trial of adjuvant Cretostimogene for Intermediate Risk NMIBC (PIVOT-006) is expected to fully enroll ahead of schedule in 2H'25[15, 55] - Cretostimogene is positioned as a backbone therapy in NMIBC, with ease of delivery and administration for patients, physicians, and practice providers[12, 50]